I Said I Would Not Explain the Technology. Here Is the Part That Is Already Public.
Jason Dussault
Chief Executive Officer, Co-Founder
.jpg)
This Post is disseminated on behalf of Intellistake Technologies Corp.
Recently, I wrote about olfaction (the sense of smell).
I made a point of saying that I would not describe how the NanoAi detection technology works. Not the materials, not the design, not the model. That still stands, and it will keep standing.
A few people came back with a fair question. If you will not tell us anything, how is anyone supposed to judge it?
That is a reasonable thing to ask. So let me do the one thing I can do.
There is a paper
It was published in Scientific Reports, part of the Nature family of journals, in March 2022. It is open access. Anyone can read it right now, for free, without asking me for permission and without me sitting in the middle explaining it.1
The author list is public. Two researchers from the Department of Biomedical Engineering at the University of Texas at Dallas. Four people from Sotech Health in Dallas, Texas, including Craig Micklich, who founded NanoAi and who would join our board on closing. And one doctor at Cleveland Clinic Abu Dhabi, where the patient work was carried out.
Our announcement described Craig as a co-author on peer reviewed research underlying the core technology.2 This is that research.
What it is not
The paper is from 2022. It describes a handheld breathalyzer built to screen for COVID. The company named on it is Sotech Health.
It is not a description of what NanoAi builds today, and I am not offering it as one. Different year, different application, different problem.
So why raise it at all?
Because most private technology companies have no public record whatsoever. You are asked to take the founder's word for everything. Here there is something on the record, written down years before we ever had a conversation, sitting in a journal where other scientists could take it apart if they wanted to.
Why I am not going to summarize it
I could walk you through what the paper says. I have decided not to.
If you are interested to get the details, you can visit the source directly, rather than from the chief executive of the company doing the deal. I have an obvious interest in how that story gets told. The journal does not.
Here is the freely accessible link: https://www.nature.com/articles/s41598-022-08321-x. Go and read it, or do not. Either way, my summary of it is worth less than the thing itself.
What I will say
Here is my own view, which you can weigh however you like.
What the peer-reviewed study validated was NanoAi’s core detection process: the underlying nanotechnology sensing science used to identify specific trace compounds at the nano level.
The target may change. It could be a compound associated with disease, or one linked to a security threat. But the fundamental challenge remains the same: detect the signal, identify what it means and produce an answer quickly enough to act on.
That is where interpretation becomes as important as detection.
Three things I would notice if I were you
If you do go and read it, I would rather flag these myself than have you find them and wonder why I stayed quiet.
The study is small. Eighty four patients, at one hospital, under an approved ethics protocol. That is enough to show a real difference. It is not enough to call anything settled.
And the commercial interest was declared. Four of the authors disclosed a significant interest in Sotech Health, and the University reviewed and managed that conflict. That is disclosure working the way it is meant to, and it is a reason to trust the process rather than doubt it.
Why this matters to us at Intellistake
A team took an idea from a computer model to a bench, from a bench to a working handheld device, from that device to a hospital with real patients and an ethics board, and then published the result somewhere it could be checked.
That is a track record. Not a forecast, not a promise. Something that already happened, written down where anyone can find it.
I am still not going to explain the technology, but in case you missed it at the start, here is the freely accessible link:
https://www.nature.com/articles/s41598-022-08321-x.
Sources
1. Banga, I., Paul, A., France, K., Micklich, B., Cardwell, B., Micklich, C., Prasad, S., "E.Co.Tech-electrochemical handheld breathalyzer COVID sensing technology,"
Scientific Reports, 2022, 12, 4370:
https://doi.org/10.1038/s41598-022-08321-x2. Intellistake Technologies Corp., news release, August 4, 2026, "Intellistake Signs C$17 Million Defense AI Acquisition Agreement for NanoAi Technologies."
Disclaimer
Intellistake has entered into a definitive agreement to acquire NanoAi and Intellistake has entered into a definitive agreement to acquire NanoAi and Completion of the NanoAi transaction remains subject to customary conditions including completion of satisfactory due diligence (including verifying title to the intellectual property of NanoAi), completion of the audit of financial statements of NanoAi, the Company maintaining a minimum cash balance of $2 million and no objection from the Canadian Securities Exchange. Closing is targeted within 60 days thereafter, subject to satisfaction of closing conditions in the definitive agreement.
This report contains "forward-looking information" concerning anticipated developments and events related to the Company that may occur in the future. Forward looking information contained in this report includes, but is not limited to, all statements in respect of the Company's growth and development, expectations regarding market growth, the operations and business segments of the Company and NanoAi, the functionality of the Company’s technology, and its benefits, the details of the proposed acquisition of NanoAi, the conditions to completion of the proposed acquisition of NanoAi, the benefits of the acquisition of NanoAi, the business model of NanoAi , the synergies between NanoAi and the Company, and bridging the gap between emerging decentralized networks and real-world industry adoption.
In certain cases, forward-looking information can be identified by the use of words such as "expects", "intends", "anticipates" or variations of such words and phrases or state that certain actions, events or results "may", "would", or "might" suggesting future outcomes, or other expectations, assumptions, intentions or statements about future events or performance. Forward-looking information contained in this report is based on certain assumptions regarding, among other things, the Company will continue to have access to financing until it achieves profitability; the Company and NanoAi satisfy all conditions necessary to close the proposed transaction; the technology and blockchain industries in which the Company intends to focus its business in will grow at the rate and in the manner expected; the ability to attract qualified personnel; the success of market initiatives and the ability to grow brand awareness; the ability to distribute Company's services; the Company creates strategies to mitigate risks associated with cryptocurrency price fluctuations; the Company remains compliant with all applicable laws and securities regulations and applicable licensing requirements; the Company engages and collaborates with local experts, as necessary, to address jurisdiction-specific matters and ensures compliance with foreign regulations to avoid penalties; the Company addresses any potential cybersecurity threats promptly and effectively; the ability of the Company to develop its technology, acquire customers and have revenue; the ability to successfully deploy the new business strategy as a result of the change of business. While the Company considers these assumptions to be reasonable, they may be incorrect.
Forward looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results to be materially different from any future results expressed by the forward-looking information. Such factors include risks related to general business, economic and social uncertainties; failure of the Company and NanoAi to satisfy all conditions necessary to close the proposed transaction; failure to raise the capital necessary to fund its operations; inability to create strategies to mitigate the risks associated with cryptocurrency price fluctuations; the costs of regulation in the digital asset industries increase to the extent that the Company is no longer generating sufficient returns for shareholders; failure to promptly and effectively address cybersecurity threats; insufficient resources to maintain its operations on a competitive basis; and the actual costs, timing and future plans differs expectations; legislative, environmental and other judicial, regulatory, political and competitive developments; the inherent risks involved in the cryptocurrency and general securities markets; the Company may not be able to profitably liquidate its current digital currency inventory, or at all; a decline in digital currency prices may have a significant negative impact on the Company's operations; the Company's success may depend on the continued involvement of key personnel, including advisors, whose involvement cannot be guaranteed; institutional adoption of decentralized AI infrastructure remains uncertain and may not occur at the pace or scale anticipated; evolving regulatory frameworks, including those related to AI (such as Canada's proposed Artificial Intelligence and Data Act) and prediction markets, may impose additional compliance burdens or restrict certain business activities; valuation figures are based on publicly available market data and internal assessments at the time of the referenced transactions and may not reflect current or future valuations; the volatility of digital currency prices; the inherent uncertainty of cost estimates and the potential for unexpected costs and expenses, currency fluctuations; regulatory restrictions, liability, competition, loss of key employees and other related risks and uncertainties; delay or failure to receive regulatory approvals; failure to attract qualified personnel, labour disputes; and the additional risks identified in the "Risk Factors" section of the Company's filings with applicable Canadian securities regulators.
Although the Company has attempted to identify factors that could cause actual results to differ materially from those described in forward-looking information, there may be other factors that cause results not to be as anticipated. Readers should not place undue reliance on forward-looking information. The forward-looking information is made as of the date of this report. Except as required by applicable securities laws, the Company does not undertake any obligation to publicly update forward-looking information.
